Compare Abbott Laboratories (ABT) vs Southern Copper Corp (SCCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Southern Copper Corp — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Southern Copper Corp trades at $166.06 (market cap $141.63B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SCCO | |
|---|---|---|
Market Cap | $166.94B | $141.63B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $218.85 |
52-Week Low | $82.57 | $90.54 |
Enterprise Value | $193.69B | $143.68B |
Dividend Yield | 2.63% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Southern Copper (SCCO) trades at $169.75, down 1.31% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 34.13% net income margin and robust earnings beats in recent quarters. Revenue growth accelerated to $13.42B in 2025, and the company maintains a solid cash flow profile with $4.75B from operations. Recent corporate actions include a $1.00 dividend and a minor stock split.
SCCO's outlook is supported by copper demand linked to AI infrastructure, but high valuation ratios (P/E 29.44) and bearish technicals pose risks. Analyst consensus is cautious with a $151.21 price target below the current price. Key risks include commodity price volatility and execution challenges in mining operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
